5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0919), a novel 5-HT1A receptor partial agonist and SSRI

  title={5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0919), a novel 5-HT1A receptor partial agonist and SSRI},
  author={Xiao-fei Chen and Zeng Jin and Ying-Zi Gong and Nan Zhao and Xiao-yun Wang and Yu-hua Ran and You-zhi Zhang and Li-ming Zhang and Yun-feng Li},

Figures and Tables from this paper

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT1A Receptor Partial Agonist/5-HT6 Receptor Full Agonist
Taking together, the current study indicated that YL-0919 exerts clear anti-PTSD effects, which might be partially mediated by ameliorating the structural neuroplasticity by increasing the expression of BDNF and the formation of synaptic proteins in the PFC.
New monoamine antidepressant, hypidone hydrochloride (YL-0919), enhances the excitability of medial prefrontal cortex in mice via a neural disinhibition mechanism.
It is demonstrated that YL-0919 enhances the excitability of mPFC via a disinhibition mechanism to fulfill its rapid antidepressant neural mechanism, which was accomplished by 5-HT1A receptor-mediated inhibition of inhibitory GABAergic interneurons.
The faster-onset antidepressant effects of hypidone hydrochloride (YL-0919)
The data suggest that YL-0919 exerts a faster antidepressant-like effect on behaviors and this effect maybe at least partially mediated by the BDNF-mTOR signaling related dendritic complexity increase in the PFC.
The Faster-Onset Antidepressant Effects of Hypidone Hydrochloride (YL-0919) in Monkeys Subjected to Chronic Unpredictable Stress
It is suggested that monkeys exposed to CUS displayed significant depression-like behaviors, and both fluoxetine hydrochloride and YL-0919 produced antidepressant effects in this model, which appeared to act faster than FLX.
The Antagonism of 5-HT6 Receptor Attenuates Current-Induced Spikes and Improves Long-Term Potentiation via the Regulation of M-Currents in a Pilocarpine-Induced Epilepsy Model
The data indicate that the antagonism of 5-HT6R may decrease the excitability of hippocampal pyramidal neurons in chronic epileptic rats and improve the impaired long-term potentiation by upregulating the expression of KCNQ2 in the M-channel.
GW117: A novel serotonin (5‐HT2C) receptor antagonist and melatonin (MT1/MT2) receptor agonist with potential antidepressant‐like activity in rodents
To evaluate the antidepressant‐like effect of compound GW117 in rodents using in vitro binding and uptake assays as well in vivo behavioral tests.


Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist
It is suggested that YL-0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-HT1A receptor agonist and 5- HT uptake blocker, showing remarkable antidepressant effects in animal models, and may be used as a new option for the treatment of major depressive disorder.
E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat
This is the first study to demonstrate that E-6801, a potent 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission.
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation
5-HT6 receptor stimulation may be a mechanism initiating some of the biochemical and behavioral outcomes of 5-HT reuptake inhibitors, such as fluoxetine, which indicates that selective 5- HT6 receptor agonists may represent a novel antidepressant drug class.
Neurochemical and behavioural effects of hypidone hydrochloride (YL‐0919): a novel combined selective 5‐HT reuptake inhibitor and partial 5‐HT1A agonist
The aim of present research was to further investigate the pharmacology of YL‐0919, which acts as a selective 5‐HT (serotonin) reuptake inhibitor (SSRI) and displays partial 5-HT1A receptor agonist properties.
5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.
Cognitive impairment in both schizophrenia and Alzheimer's disease could be improved by 5-HT6R antagonists, because these compounds increase the number of NCAM PSA-immunoreactive neurons in the dendate gyrus, inhibit mTOR and Fyn-tyrosine kinase and interact with DARPP-32.
Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration
The current findings suggest an important role for these 5-HT6R ligands as mood modulators in schizophrenia, however, it is necessary to explore the physiological mechanisms involved in this process in greater detail.
Therapeutic Potential of 5-HT6 Receptor Agonists.
Surprisingly, some studies have shown that both 5-HT6R agonists and antagonists exert similar procognitive activities, and this article summarizes the hypotheses that could explain this paradox.
5-HT6 receptor agonism facilitates emotional learning
The results indicate antidepressant efficacy and facilitation of emotional learning by 5-HT6 receptor agonism via mechanisms that promote neuronal plasticity in caudate putamen, hippocampus, and PFC.